News Channels

21 Nov 2023 Bioxodes closes €12 million in Series A funding round
21 Nov 2023 First Subject Enrolled in Phase 1 Study of MRX-5
21 Nov 2023 Chengdu Origen and Vanotech Announce First Patient Dosed in VAN-2201 Phase 1 Trial of Gene Therapy for Wet Age-Related Macular Degeneration
21 Nov 2023 Imvax Presents New Data at 2023 SNO Annual Meeting Supporting its Lead Program, IGV-001, in Newly Diagnosed Glioblastoma
21 Nov 2023 MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
21 Nov 2023 BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor
21 Nov 2023 Merck to Acquire Caraway Therapeutics, Inc.
20 Nov 2023 Omnix Medical Receives U.S. FDA Approval of a Phase II Trial of its Next-Generation Anti-Infective OMN6
20 Nov 2023 Antibody Target, Technology & Pipeline Database: a cost-effective tool to stay tuned with latest information about therapeutic antibodies
20 Nov 2023 OCEANIC-AF study stopped early due to lack of efficacy
18 Nov 2023 Medicenna Announces Compelling Survival Benefit from Phase 2b Study of Bizaxofusp in Recurrent Glioblastoma at the 28th Annual Meeting of the Society for NeuroOncology
18 Nov 2023 Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes
18 Nov 2023 AskBio Announces First Patient Randomized in Phase 1 Trial of AB-1005 (AAV2-GDNF) Gene Therapy for Multiple System Atrophy-Parkinsonian Type (MSA-P)
17 Nov 2023 Almirall Receives European Commission Approval of EBGLYSS® (lebrikizumab) for Moderate-to-Severe Atopic Dermatitis
17 Nov 2023 Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE
17 Nov 2023 Truqap (capivasertib) plus Faslodex approved in the US for patients with advanced HR-positive breast cancer
17 Nov 2023 Polaris Group Initiates Rolling Submission of Biologic License Application (BLA) for ADI-PEG 20 with U.S. FDA to Treat Malignant Pleural Mesothelioma
17 Nov 2023 Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting
17 Nov 2023 Antengene Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day
17 Nov 2023 FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up